Overview

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

Status:
RECRUITING
Trial end date:
2025-12-12
Target enrollment:
Participant gender:
Summary
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013 after treatment.The treatment duration for Part A MAD study is 52 weeks and the duration for Part B study is 26 weeks.
Phase:
PHASE2
Details
Lead Sponsor:
Shaanxi Micot Pharmaceutical Technology Co., Ltd.